Internal Iliac Artery Ligation During Management of Placenta Accreta Spectrum
NCT ID: NCT04593303
Last Updated: 2022-04-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
42 participants
INTERVENTIONAL
2020-09-01
2022-01-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Ligation of Anterior Internal Iliac Artery With Conservative Management of Partial or Focal Placenta Accreta Spectrum
NCT05471102
Conservative Management of Morbidly Adherent Anterior Situated Placenta
NCT04579172
Bilateral Uterine Artery Ligation in PPC Technique for Management of PAS
NCT05314595
the Efficacy and Safety of the 3-steps Conservative Approach in the Management of Placenta Accreta Spectrum (a Novel Technique)
NCT05191316
Conservative Surgical Novel Technique of Placenta Accreta in Menoufia University Hospital
NCT04161521
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Steps:
* Abdominal wall Incision will be done either in the midline or transverse suprapubic incision.
* Opening the abdominal wall in layers.
* Uterine incision will be done at the upper border of the placenta determined at laparotomy by naked eye.
* Delivery of the baby. Then the placenta will be left in place till doing devascularisation and bladder dissection
* Participants then will be, divided into two groups Participants in internal iliac group will undergo internal iliac artery ligation before bladder dissection Participants in no internal iliac artery group will undergo bladder dissection immediately without internal iliac artery ligation
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Internal iliac artery group
Bilateral internal Iliac artery ligation will be done followed by urinary bladder dissection then bilateral uterine artery ligation then manual removal of the placenta then cervico isthmic compression suture. (holding the upper border of the cervix by 4 Allis's forceps then suturing the cervix with the anterior uterine wall using continuous suture), Nelaton catheter18 gauge or Hegar's dilator will be inserted inside cervical canal during Cervico isthmic tamponed suture to ensure patency of cervical canal. .
Internal iliac artery ligation with cervicoisthmic compression suture
Retroperitoneal approach will be performed to ligate both internal iliac arteries before bladder dissection followed by cervicoisthmic compression suture application at placental bed
No internal iliac artery group
Bladder dissection then bilateral uterine artery ligation then cervico isthmic suture without internal iliac artery ligation
Cervicoisthmic compression suture without Internal iliac artery ligation
Bladder dissection followed by cervicoisthmic compression suture application at placental bed without Internal iliac artery ligation
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Internal iliac artery ligation with cervicoisthmic compression suture
Retroperitoneal approach will be performed to ligate both internal iliac arteries before bladder dissection followed by cervicoisthmic compression suture application at placental bed
Cervicoisthmic compression suture without Internal iliac artery ligation
Bladder dissection followed by cervicoisthmic compression suture application at placental bed without Internal iliac artery ligation
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. History of ' 3 caesarean deliveries or less .
3. Pregnant female diagnosed to have none complicated medical disorders e.g. Uncontrolled hypertension, Uncontrolled preeclampsia, Uncontrolled Diabetes mellitus .
4. If ≥2 of the following criteria present by trans abdominal ultrasound and color Doppler examination:
a-Loss of clear zone c-Placental lacunae. e-Placental bulge. g-Utero-vesical. hyper vascularity. i-Bridging vessels. b-Myometrial thinning. d-Bladder wall interruption. f-Focal exophytic mass. h-Subplacental.hyper vascularity. j-Lacunae feeder vessels.
5. Placenta increta or percreta according to FIGO classification (2019)including:
1\. Grade II(FIGO 2019 ) 8:Abnormally invasive placenta (Increta)
Clinical criteria):
At laparotomy Abnormal macroscopic findings over the placental bed: bluish/purple coloring, distension (placental "bulge").
Significant amounts of hyper vascularity (dense tangled bed of vessels or multiple vessels running parallel craniocaudally in the uterine serosa).
No placental tissue seen to be invading through the uterine serosa. Gentle cord traction results in the uterus being pulled inwards without separation of the placenta (so-called the dimple sign).
Histologic criteria:
Hysterectomy specimen or partial myometrial resection of the increta area shows placental villi within the muscular fibers and sometimes in the lumen of the deep uterine vasculature (radial or arcuate arteries),if failed conservative therapy.
2\. Grade III(FIGO 2019)8: Abnormally invasive placenta (Percreta) Grade 3a: Limited to the uterine serosa Clinical criteria At laparotomy Abnormal macroscopic findings on uterine serosal surface (as above) and placental tissue seen to be invading through the surface of the uterus.
No invasion into any other organ, including the posterior wall of the bladder (a clear surgical plan can be identified between bladder and uterus).
Histologic criteria Hysterectomy specimen showing villous tissue within or breaching the uterine serosa.
Exclusion Criteria
2. History of more than 3 caesarean deliveries.
3. Patient refusing conservative management.
4. Uncontrolled maternal diabetes, hypertension, Preeclampsia and Decompensated Rheumatic Heart Disease.
5. Placenta accrete( FiGO 2019 ) 8classification Grade I:
Abnormally adherent placenta (placenta adherenta or accreta) Clinical criteria Macroscopically, the uterus shows no obvious distension over the placental bed (placental "bulge"), no placental tissue is seen invading through the surface of the uterus, and there is no or minimal neovascularity Histologic criteria Microscopic examination of the placental bed samples from hysterectomy specimen shows extended areas of absent decidua between villous tissue and myometrium with placental villi attached directly to the superficial myometrium The diagnosis cannot be made on just delivered placental tissue nor on random biopsies of the placental bed.
3\. Grade III(FIGO 2019)8: Abnormally invasive placenta (Percreta) Grade 3b: With urinary bladder invasion Clinical criteria At laparotomy Placental villi are seen to be invading into the bladder but no other organs. Clear surgical plan cannot be identified between the bladder a uterus. Histologic criteria Hysterectomy specimen showing villous tissue breaching the uterine serosa and invading the bladder wall tissue or urothelium.
Grade 3c: With invasion of other pelvic tissue/organ Clinical criteria At laparotomy Placental villi are seen to be invading into the broad ligament, vaginal wall, pelvic sidewall or any other pelvic organ (with or without invasion of the bladder).
Histologic criteria Hysterectomy specimen showing villous tissue breaching the uterine serosa and invading pelvic tissues/organs (with or without invasion of the bladder) For the purposes of this classification, "uterus" includes the uterine body and uterine cervix.
18 Years
35 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mansoura University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mohamed Taman
Consultant
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Faculty of Medicine
Al Mansurah, Dakahlia Governorate, Egypt
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Sawada M, Matsuzaki S, Mimura K, Kumasawa K, Endo M, Kimura T. Successful conservative management of placenta percreta: Investigation by serial magnetic resonance imaging of the clinical course and a literature review. J Obstet Gynaecol Res. 2016 Dec;42(12):1858-1863. doi: 10.1111/jog.13121. Epub 2016 Aug 16.
Hecht JL, Baergen R, Ernst LM, Katzman PJ, Jacques SM, Jauniaux E, Khong TY, Metlay LA, Poder L, Qureshi F, Rabban JT 3rd, Roberts DJ, Shainker S, Heller DS. Classification and reporting guidelines for the pathology diagnosis of placenta accreta spectrum (PAS) disorders: recommendations from an expert panel. Mod Pathol. 2020 Dec;33(12):2382-2396. doi: 10.1038/s41379-020-0569-1. Epub 2020 May 15.
Jauniaux E, Ayres-de-Campos D, Langhoff-Roos J, Fox KA, Collins S; FIGO Placenta Accreta Diagnosis and Management Expert Consensus Panel. FIGO classification for the clinical diagnosis of placenta accreta spectrum disorders. Int J Gynaecol Obstet. 2019 Jul;146(1):20-24. doi: 10.1002/ijgo.12761.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MS.20.09.1255
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.